Antibiotic susceptibility of Streptococcus pneumoniae, causing meningitis in Moscow


DOI: https://dx.doi.org/10.18565/epidem.2019.9.1.48-55

Koroleva M.A., Koroleva I.S., Beloshitsky G.V., Gruber I.M.

1 Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2 I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia
Objective. Determination of antibiotic susceptibility of Streptococcus pneumoniae isolated from patients with pneumococcal meningitis in Moscow.
Materials and methods. For the period 2006–2017, 99 strains were studied. The susceptibility of Streptococcus pneumoniae to a number of antibacterial drugs was established by the E-tests and diffusion test.
Results. The level of resistance to benzylpenicillin was 5.1%, to erythromycin – 11.1%. The proportion of multiresistant strains was determined at the level of 6.1%. An increase in the susceptibility potential of pneumococcus to benzylpenicillin, trimethoprim-sulfamethoxazole, levofloxacin, ceftriaxone was noted. On the contrary, an increase in the strains potential of resistance to macrolides and tetracycline was revealed. In relation to the serotype landscape of resistant strains, serotypes included in the 13-valent conjugated pneumococcal vaccine: 6B, 19F, 3, 23F, 18C and 19F, 14, 6A, 23F, 7F, respectively, prevailed both in the pre-vaccination and the post-vaccination period.
Conclusion. Considering the increasing incidence of pneumococcal meningitis, high mortality rates, as well as the development of antibacterial resistance mechanisms in pneumococcal strains, there is a growing need to increase vaccination coverage of children to the targeted indicator and expand immunization programs against pneumococcal infection.
Keywords: pneumococcal infection, pneumococcus, antibiotic resistance, meningitis
Read entire article

Literature

  1. Musher D.M. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin. Infect. Dis. 1992; 14: 801–7.
  2. Klugman K.P. Pneumococcal resistance to Antibiotics. Clin. Microbiol. Rev. 1990; 3(2): 171–96.
  3. Jacobs M.R., Good C.E., Beall B., Bajaksouzian S., Windau A.R., Whitney C.G. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J. Clin. Microbiol. 2008; 46: 982–90.
  4. Klugman K.P., Lonks J.R. Hidden epidemic of macrolide-resistant pneumococci. Emerg. Infect. Dis. 2005; 1: 802–7.
  5. Imohl M., Reinert R.R., van der Linden M. Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany. Int. J. Med. Microbiol. 2015; 305(7): 776–83.
  6. Koroleva I.S., Koroleva M.A., Beloshitsky G.V. [Meningococcal infection and purulent bacterial meningitis in Russia. 2017. Information-analytical review]. Moscow, 2018; 27–32. (In Russ.).
  7. Koroleva I.S., Beloshitsky G.V. [Meningococcal infection and purulent bacterial meningitis. Guide to laboratory diagnosis]. Moscow: Medicinskoe informacionnoe agentstvo, 2007. 112 p. (In Russ.).
  8. Weil-Oliver C., van der Linden M., de Schutter I., Dagan R., Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect. Dis. 2012; 12: 207.
  9. Mokaddas E., Albert M.J., Impact of pneumococcal conjugate vaccine on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait. Vaccine 2012; 30(6): 37–40.
  10. Regev-Yochay G., Rahav G., Riesenberg K. et al. Initial effects of the national PCV7 childhood immunization program on adult invasive pneumococcal disease in Israel. PloS ONE 2014 (9): e88406. DOI: 10.1371/ journal.pone.0088406.
  11. Lai C.C., Lin S.H., Liao C.H., Sheng W.H., Hsueh P.R. Decline in the incidence of invasive pneumococcal disease at medical center in Taiwan, 2000–2012. BMC Infect. Dis. 2014; 14: 76. https://doi.org/10.1186/1471-2334-14-76


About the Autors

Maria А. Koroleva, Cand. Med. Sci., Senior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; е-mail: korolevamaria389@mail.ru; ORCID: http://orcid.org/0000-0002-3450-4851
Irina S. Koroleva, MD, Head, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; е-mail: irina-korol@yandex.ru; ORCID: http://orcid.org/0000-0003-0578-146X
Grigoriy V. Beloshitsky, Cand. Med. Sci., Senior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; е-mail: g-belosh1@yandex.ru
Irina M. Gruber, MD, Head, Laboratory of Experimental Microbiology, I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow; Russia; e-mail: igruber_ instmach@mail.ru


Similar Articles

Back to Content

Бионика Медиа